SynthesisMedicine2026
Correlation between MMP-3-1171 5A/6A polymorphism and the risk of Alzheimer's disease: A meta-analysis.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPrevious studies of matrix metalloproteinase-3 (MMP-3) -1171 5A/6A polymorphism in Alzheimer's disease (AD) have been extensively investigated; however, the results from different studies are inconsistent. This meta-analysis was performed to clarify the link between this variant and AD.
methodsWe searched PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang Database. The associations were calculated as odds ratios with the corresponding 95% confidence intervals (CIs).
results7 case-control studies with a total of 1457 cases and 1959 controls were included. Overall, there was no significant association between matrix metalloproteinase-3-1171 5A/6A polymorphism and AD risk in all genetic models (the allele model 5A vs. 6A: odds ratio (OR) = 1.06, 95% CI 0.82-1.36, P = .65; the heterozygote model 5A/6A vs. 6A/6A: OR = 0.98, 95%CI 0.75-1.28, P = .89; the homozygous model 5A/5A vs. 6A/6A: OR = 1.20, 95%CI 0.70-2.07, P = .51; the dominant model 5A/6A + 5A/5A vs. 6A/6A: OR = 1.03, 95%CI 0.76-1.40, P = .85; the recessive model 5A/5A vs. 5A/6A + 6A/6A: OR = 1.24, 95%CI 0.80-1.93, P = .34). In subgroup analysis by ethnicity, no significant difference was detected in both Caucasians and Asians between matrix metalloproteinase-3-1171 5A/6A polymorphism and AD risk. Similar results were obtained in sensitivity analysis.
conclusionIn summary, the present meta-analysis suggests that MMP-3-1171 5A/6A polymorphism may not be associated with genetic susceptibility to AD in the general population. Given the limited sample size and study heterogeneity, findings warrant cautious interpretation and require verification through larger, well-designed trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.